News

Chevron Engages in Venture Global's LNG Project Discussions

Chevron Engages in Venture Global's LNG Project Discussions

Chevron Expresses Interest in Venture Global LNG Project

Recently, Chevron Corporation (NYSE: CVX) has taken steps to become involved in discussions regarding Venture Global, Inc.'s (NYSE: VG) proposal to delay the operational deadline for its Plaquemines LNG export terminal.

This action reflects growing tensions between Venture Global and its long-term customers, particularly as project timelines and commitments come into question.

Overview of the LNG Project

The Plaquemines LNG facility, located approximately 20 miles south of New Orleans, is currently under construction. The project has been actively built since 2021, aiming to create a robust infrastructure for liquefied natural gas export.

Upon completion, both phases of Plaquemines LNG are projected to achieve a remarkable production capacity of at least 20 million metric tons of LNG annually. This production is a significant boost to the U.S. LNG export landscape.

In a recent regulatory update, U.S. authorities approved Venture Global's request to increase the export capacity of Plaquemines LNG from 24 million to 27.2 million metric tons per year, indicating a proactive response to the growing demand for LNG.

Historical Context of the Project Delays

In the previous month, Venture Global submitted a request to the Federal Energy Regulatory Commission (FERC) to extend its in-service deadline from September 2026 to December 2027. The extension request was attributed to various challenges including construction delays, supply chain disruptions, and adverse weather conditions.

Diversely, the Federal Register has a protocol that allows for public comments on such requests, granting a 15-day window for stakeholders to voice their opinions. Decisions on contested requests are typically made within a 45-day timeframe.

Venture Global maintains that this extension request will not affect the anticipated commercial operation dates for the project phases, which are planned to move forward as originally scheduled.

Chevron's Commitment to the Venture Global Partnership

In light of its two long-term Sales and Purchase Agreements established in 2022, Chevron committed to purchasing a total of 2 million tonnes per annum (MTPA) of LNG from Venture Global's facilities. These are critical agreements in ensuring Chevron's LNG supply chain is fortified and reliable.

Chevron's agreements represent a strategic investment in both Plaquemines LNG and CP2 LNG, highlighting the company's significant stake in the success of these projects.

Moreover, recent news from Chevron indicates plans to initiate drilling at the Korikori-1 exploration well off the coast of Suriname. With Chevron holding a 40% interest in this project through Suriname Exploration Limited, the company continues to expand its offshore investments and capabilities.

Investors interested in gaining exposure to Chevron can consider financial instruments such as the EA Series Trust Strive U.S. Energy ETF (NYSE: DRLL) or the SPDR Select Sector Fund – Energy Select Sector (NYSE: XLE), both of which include CVX stock as part of their portfolios.

Chevron's Stock Performance: As of recent trading sessions, Chevron shares have shown resilience, recently trading at $152.85, indicating a modest increase of 0.30% during premarket activities.

Frequently Asked Questions

What is the current status of Venture Global's LNG project?

The Plaquemines LNG project is currently under construction, aiming for completion to achieve a production capacity of over 20 million metric tons per year.

Why has Chevron requested involvement in Venture Global's project?

Citing its significant financial commitments to the project, Chevron seeks to ensure its interests are protected amid delays in project timelines.

What challenges has Venture Global faced recently?

Venture Global has encountered construction delays, supply chain disruptions, and adverse weather impacts that have necessitated requests for project deadline extensions.

What are the implications of the extension request?

The extension request could affect long-term planning and expectations for LNG supply to customers, including Chevron, but is stated to have no impact on expected commercial operations.

Where can investors monitor the stock performance of Chevron?

Investors can track Chevron and related stocks through financial platforms offering updates on stock prices and performance indexes, like those listed under the energy sector ETFs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lassa's Wintus 3: Boosting Winter Tyre Game for 2026

Updated Category News Views 2

Rolling Through Winter: Lassa's Next Step Ever felt like you were skating on thin ice with your vehicle in winter? That's why Lassa has cranked out the Wintus 3—a tyre making waves in the chilly game. Now, we're not talking about your run-of-the-mill rubber. This is a strategic play by a Turkish powerhouse, Brisa, aimed squarely at those who rely on light commercial...

Continue Reading
Dimora Medical Boosts Advanced Wound Care at HS Conference

Updated Category News Views 44

Empowering the HS Community with Innovations Look, if you’ve walked a mile in someone else's shoes—particularly ones dealing with hidradenitis suppurativa (HS)—you’d know what a relentless grind managing those exuding wounds can be. Dimora Medical, known for navigating the tricky territory of wound care, threw its hat into the ring at the HS Connect Empower...

Continue Reading
Solenis Appoints Brendy Lange to Lead Americas Growth

Updated Category News Views 6

New Leadership at Solenis Change is brewing at Solenis, and it's set to ripple across the water treatment industry like a stone in a pond. Brendy Lange's appointment as Chief Business Officer, Americas, promises to shake things up in a firm as committed to innovation as Solenis. This seasoned executive, scooped from the ranks of Dow Chemical, steps in with a mandate to...

Continue Reading
Ractigen's LiCO™ Platform Hits Extrahepatic Milestones

Updated Category News Views 6

Breaking New Ground in RNA Therapeutics Hey, in the world of biotech, landing a meaningful delivery system is like striking gold, and it seems Ractigen Therapeutics just found a shiny nugget. Their latest study on the LiCO™ platform, living and breathing in the pages of Molecular Therapy - Nucleic Acids, maps out a path to some serious therapeutic territory. These guys...

Continue Reading
Galien Recognizes Kerry for Transformative Global Health Work

Updated Category News Views 10

Kerry's Legacy: A Symbol of Global Unity In the ever-thickening jungle of geopolitics and global health, it's rare to find a beacon as steadfast as John Kerry. This year, The Galien Foundation saw fit to honor him with the 2026 Roy Vagelos Pro Bono Humanum Award for Global Health Equity. This ain't just some shiny trinket—it’s a testament to his lifetime of ripping...

Continue Reading
Cboe Clear's US Move: A New Chapter with SEC Nod

Updated Category News Views 4

Clearing the Path for New Beginnings The ink's barely dry on Cboe Clear U.S.'s recent SEC registration, and it's already setting tongues wagging among market old-timers. This move to clear binary securities options alongside futures isn't just a step up; it's a signal flare for ambitious innovation. The Nuts and Bolts: SEC Registration So, what's the big to-do? Cboe Clear...

Continue Reading
Rakuten Medical's Long-Term Data Shows Promise

Updated Category News Views 5

This Isn't Just Another Cancer Update Alright, folks, let's unwrap what's happening today with Rakuten Medical. They've thrown some serious numbers into the ring at the ESMO Congress 2026 in Madrid. We're talking long-term follow-up results of their ASP-1929 photoimmunotherapy combined with pembrolizumab in tackling recurrent and metastatic head and neck squamous cell...

Continue Reading
SAFE Structure Designs Backs Prosthetic Nonprofit 50 Legs

Updated Category News Views 3

A Partnership Rooted in Service and Faith Let's face it, support from major companies for nonprofits isn't exactly commonplace. But every so often, you run into a partnership that catches your eye, and this one's got a little extra heart. SAFE Structure Designs, known for its defense engineering prowess in Las Vegas, is throwing its weight behind Clearwater's 50 Legs....

Continue Reading
S&P Global's New Dashboard: Unpacking Data Insights

Updated Category News Views 3

An Interactive Take on Digital Infrastructure The geniuses over at S&P Global Ratings have just unleashed a shiny new tool for number crunchers and market hawks who can't get enough data center action—an interactive dashboard. Maybe not everyone’s cup of tea, but hey, in the dog-eat-dog world of digital infrastructure, any edge counts. What's in the Data Center Soup?...

Continue Reading
TORL Bio's Ixo-V Drug Shows Promise in Combatting GCT

Updated Category News Views 5

A Beacon of Hope in Germ Cell Tumor Treatment There's something brewing in the oncology world that's worth a nod. TORL BioTherapeutics has rolled out some interesting preliminary data for their hopeful cancer buster, ixotatug vedotin, or Ixo-V. This study is part of a wider effort to take a swing at recurrent germ cell tumors (GCTs) with some tough results already making...

Continue Reading

Top 5 Most Recently Viewed Articles

MediaAlpha Set for Q3 2024 Financial Results Presentation

Updated Category News Views 78

MediaAlpha's Upcoming Financial Report Announcement MediaAlpha, Inc. (NYSE: MAX), based in Los Angeles, has exciting news for its investors and stakeholders. The company is gearing up to announce its financial results for the third quarter of 2024 on an upcoming Wednesday. This announcement will take place after the market closes, providing important insights into the...

Continue Reading
Understanding Recent Trends in Canadian Stocks and Markets

Updated Category News Views 329

Canadian Stock Market Overview Recently, the Canadian stock market experienced a decline, reflecting a challenging trading environment. The decline was multifaceted, with notable tumbles in sectors such as the Consumer Staples, REITs, and Healthcare, which significantly influenced overall market performance. Investors and analysts are keenly observing these fluctuations,...

Continue Reading
Discover Key Trends in Network Observability for IT Success

Updated Category News Views 137

Emerging Trends in Network Observability Join experts as they discuss how IT leaders can adapt observability tools to meet modern network challenges. Enterprise Management Associates (EMA) is hosting an insightful webinar titled "Your NetOps Tools Are Aging Faster Than Your Network: 5 Emerging Trends That Are Reshaping Network Observability." Shamus McGillicuddy, Vice...

Continue Reading
Realbotix Secures Payment in Genesis Restructuring Efforts

Updated Category News Views 74

Realbotix Achieves Major Financial Recovery Realbotix Corp. (TSX-V: XBOT | Frankfurt Stock Exchange: 76M0.F | OTC: XBOTF) is making waves in the news by recently securing a significant cash payment of US$743,500 as part of its ongoing restructuring efforts with Genesis Global Capital. This milestone is a positive step for the Company as it works through the challenges of...

Continue Reading
Immedica Pharma's Loargys: Pioneering Hope in Rare Disease

Updated Category News Views 210

Game-Changing Approval or Just Another Hype Train? Time for a gut check: Immedica Pharma just made waves with its Loargys® (pegzilarginase-nbln), snagging accelerated FDA approval for treating hyperargininemia tied to Arginase 1 Deficiency (ARG1-D). So what's the big deal? Well, basically, we're talking about a breakthrough here—it's the first therapy proven to lower...

Continue Reading